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An accumulating body of evidence suggests that the activity of the mineralocorticoid, aldosterone, in the brain via the mineralocorticoid receptor (MR) plays an important role in the regulation of blood pressure. MR was recently found in vasopressin and oxytocin synthesising
magnocellular neurosecretory cells (MNCs) in both the paraventricular (PVN) and supraoptic
(SON) nuclei in the hypothalamus. Considering the physiological effects of these hormones, MR
in these neurones may be an important site mediating the action of aldosterone in blood pressure regulation within the brain. However, aldosterone activation of MR in the hypothalamus
remains controversial as a result of the high binding affinity of glucocorticoids to MR at
substantially higher concentrations compared to aldosterone. In aldosterone-sensitive epithelia,
the enzyme 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) prevents glucocorticoids from
binding to MR by converting glucocorticoids into inactive metabolites. The present study aimed
to determine whether 11b-HSD2, which increases aldosterone selectivity, is expressed in MNCs.
Specific 11b-HSD2 immunoreactivity was found in the cytoplasm of the MNCs in both the SON
and PVN. In addition, double-fluorescence confocal microscopy demonstrated that MR-immunoreactivity and 11b-HSD2-in situ hybridised products are colocalised in MNCs. Lastly, single-cell reverse transcriptase-polymerase chain reaction detected MR and 11b-HSD2 mRNAs
from cDNA libraries derived from single identified MNCs. These findings strongly suggest that
MNCs in the SON and PVN are aldosterone-sensitive neurones.
Key words: oxytocin, vasopressin

Magnocellular neurosecretory cells (MNCs) in the supraoptic (SON)
and paraventricular (PVN) nuclei synthesise and release the neurohypophysial hormones, vasopressin (VP) and oxytocin (OT), from terminals in the posterior lobe of the pituitary. These two hormones
are released into the general circulation in response to decreases in
blood volume, pressure or extracellular fluid tonicity. VP plays an
important role in the elevation of blood pressure by exerting vasoconstricting and antidiuretic actions in the kidney (1,2). OT acts as
a natriuretic factor promoting sodium excretion by the kidney (3,4),
in addition to the well-known effects of OT in female reproduction;
OT promotes the contraction of both smooth muscle in the uterus
during labour and in myoepithelial cells in the mammary gland during milk ejection (5). In addition to VP and OT synthesising MNCs,
parvocellular neurones are located in both the dorsal cap and
ventrolateral subdivisions of the PVN. Some parvocellular neurones
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are presympathetic, affecting renal sympathetic outflow supporting
the maintenance of the fluid/electrolyte balance (6,7). Because the
activity of parvocellular presympathetic neurones is, at least partly,
regulated by the somatodendritic release of VP from MNCs within
the PVN (8), VP coordinates neurohumoral homeostatic responses
via cross-talk between the MNCs and the autonomic parvocellular
cells in the PVN. MNCs therefore precisely coordinate neuroendocrine and autonomic responses to maintain optimal blood pressure within a constantly changing physiological condition.
We recently demonstrated that the nonvoltage-dependent,
amiloride-sensitive epithelial Na+ channels (ENaCs) are present in
the MNCs and mediate a Na+ leak current that modulates the
membrane potential of MNCs (9). Because the release of OT and
VP hormones from the neurohypophysis depends largely on the
frequency and pattern of action potentials in their synthesising
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neurones (2,10), the presence of ENaC in MNCs implies that activation of ENaC comprises one way of modulating hormone secretion according to physiological demands. Expression of ENaC in
epithelia is largely regulated by aldosterone through the mineralocorticoid receptor (MR) (11–15). The presence of MR in MNCs
(9,16–20) therefore indicates that ENaC expression in MNCs may
also be promoted by aldosterone. However, not only is there no
information regarding the physiological functions of MR in MNCs,
but also aldosterone activation of MR in the hypothalamus is
also controversial. Because MR binds with high affinity to aldosterone as well as to corticosteroids (21–24), and because the
concentration of corticosterone in the brain is substantially higher
than that of aldosterone, MRs in the brain are considered to be
largely occupied by corticosterone (25). Aldosterone-sensitive
epithelial tissues express the enzyme, 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2), which converts corticosterone into an
inactive metabolite to increase aldosterone selectivity to MR
(26–28). Thus, the co-localisation of MR and 11b-HSD2 in the
same cells indicates that the cells are sensitive to aldosterone
(29–31).
Although several studies using the reverse transcriptase-polymerase chain reaction (RT-PCR) consistently detected 11b-HSD2
mRNA in both the hypothalamus (32–36) and in tissue micropunches from the PVN (35), these studies provided no cellular localisation of 11b-HSD2 in the hypothalamus. In situ hybridisations of
11b-HSD2 in rat brain were reported previously, although no specific labelling in the SON or PVN was reported (37–39). However,
these in situ hybridisation studies were not intended to specifically
detect 11b-HSD2 mRNA in MNCs or in the hypothalamus, and the
autoradiographical method was probably not sufficiently sensitive
to detect relatively limited mRNA at the cellular level. More
recently, immunocytochemical localisations of 11b-HSD2 in the
brain were reported, although no immunoreactivity to 11b-HSD2 in
the PVN was found (40,41). The antibody used in these previous
studies, however, shows nonspecific binding in the cellular nuclei,
and thus a more diluted concentration was needed. Although this
approach was adequate for detecting cells that express relatively
abundant amounts of 11b-HSD2, such as cells in the nucleus of
the solitary tract known to regulate sodium appetite in response to
aldosterone (40), the study might have overlooked the relatively
scarce amount of 11b-HSD2 in the MNCs. The present study therefore specifically aimed to re-evaluate the presence of 11b-HSD2 in
MR-expressing MNCs in both the SON and PVN using experimental
techniques of immunocytochemistry, in situ hybridisation and single-cell RT-PCR.

Materials and methods
Animals
Male Wistar and Wistar–Kyoto (WKY) rats were examined (320–380 g body
weight; Harlan Laboratories, Indianapolis, IN, USA). The rats with access to
food and water available ad lib. were housed in a room under a 12 : 12 h
light/dark cycle. All protocols were approved by the Institutional Animal Care
and Use Committee at Louisiana State University.

Immunocytochemistry
Animals were deeply anaesthetised with sodium pentobarbital (50 mg/kg,
i.p.) and transcardially perfused with 0.01 M sodium phosphate-buffered saline (PBS) (pH 7.2) followed by 4% paraformaldehyde in 0.1 M sodium phosphate buffer (PB, pH 7.2). The heads were postfixed in the same fixative for
1–3 days. The brains were extracted and infiltrated with 20% sucrose in
0.1 M PB until they sank to the bottom or for overnight. The coronal sections at 40 lm were obtained by a sliding microtome (SM2010R; Leica,
Mannheim, Germany).
Free-floating brain sections were incubated with a monoclonal anti-MR
antibody or polyclonal anti-11b-HSD2 antibody diluted in PBS containing
0.5% Triton X-100 for 48–72 h at 4 °C. Four different anti-MR monoclonal
antibodies (rMR365 4D6, rMR1-18 1D5, MRN2 2B7 and MRN3 3F 10), developed by C. E. Gomez-Sanchez, were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and
maintained by Department of Biology, The University of Iowa (Iowa City, IA,
USA). All of these antibodies in our pilot study displayed essentially identical
distribution of immunoreactivity in the hypothalamic region. MRN3 3F10
was selected for the present study because it showed the most robust
immunoreactivity in the hypothalamus. The production and characterisation
of these MR antibodies have been described in great detail previously (42).
A range of different antibody dilutions was tested (1 : 100 to 1 : 10 000)
for anti-MR and a dilution of 1 : 500 produced optimal signal-to-noise. The
polyclonal anti-11b-HSD2 antibody was raised against a synthetic peptide
corresponding to amino acids of 129–400 (polyhistidine N-terminal) from
rat 11b-HSD2 (AB1296; Chemicon, Temecula, CA, USA). Characteristics of
the 11b-HSD2 antibody in immunocytochemistry was initially tested at dilutions between 1 : 5000 and 1 : 80 000 in nine animals. Consistent with the
report of Geerling et al. (43), this antibody labelled all neuronal nuclei at
dilution under 1 : 25 000. Although we agree with the interpretation of the
ubiquitous nuclear labelling at higher antibody concentrations being nonspecific cross-reactivity, careful observation of sections treated with the
antibody at dilutions below 1 : 10 000 revealed that 11b-HSD2 immunoreactivity was also observed in the cytoplasm of MNCs in the SON and the
PVN. A dilution of 1 : 10 000 for anti-11b-HSD2 antibody produce optimal
signal-to-noise staining of the cytoplasm of MNCs in the SON and PVN.
Omission of the primary antibody was used as a negative control and produced no detectable immunoreactivity. In addition, immunocytochemistry of
anti-11b-HSD2 antibody was tested on the kidney sections where the
presence of 11b-HSD2 is known (44).
For light microscopy, the brain sections were subsequently incubated with
appropriate biotinylated secondary antibodies (dilution 1 : 200; Vector, Burlingame, CA, USA) followed by the standard ABC-diaminobenzidine (DAB)
procedure per the protocol provided by Vector. The brain sections were
mounted on gelatin-coated slides, dehydrated, cleared and cover slipped
with Permount. Light microscopic images were acquired digitally with a
microscope (Nikon Eclipse 80i; Nikon, Tokyo, Japan) equipped with a digital
camera (Nikon DS-QiMc). Digital images were minimally altered in IMAGEJ
(NIH, Bethesda, MD, USA) with changes in dynamic range.
For double-immuno labeling of MR with VP or OT, specific anti-VP-neurophysin (VP-NP) and OT-NP polyclonal antibodies raised in rabbits were used
at a 1 : 20 000 dilution (provided by Alan Robinson, UCLA, CA). First, the
brain sections were incubated with MRN3 3F10 as described above and
labeled with DyLight 488-conjugated goat anti-mouse IgG (1 : 500; Jackson
ImmunoResearch, West Grove, PA, USA). The MR-labeled brain sections were
subsequently incubated with anti-VP-NP or anti-OT-NP antibody for overnight and labeled with DyLight 649-conjugated goat anti-rabbit IgG (1 : 500;
Jackson ImmunoResearch). The brain sections were examined and confocal
images were acquired at 1024 9 1024 format (Leica TCS SP2 spectral confocal microscope, Mannheim, Germany). The optical sections were 1 lm thick
and viewed in stacks of three sections using ImageJ software (NIH).

© 2015 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of
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Optical density (OD) measurements of
immunocytochemistry
Brain sections obtained from six brains from each of the Wistar and WKY
rats were treated for MR-immunocytochemistry concurrently under the
same conditions. Digital photomicrographs of both sides of the SON (n = 6)
were acquired every 200 lm from DAB-stained brain sections that contained the nucleus. Each image was digitised with 12-bit intensity levels
using a microscope (Nikon Eclipse 80i) equipped with a digital camera
(Nikon DS-QiMc). All images were taken at the same exposure (time and
length) and light intensity. Average OD value of densitometric measurements
of the entire SON and the magnocellular division of the PVN were obtained
from the photomicrographs using IMAGEJ (NIH). To normalise OD values, areas
outside the SON and PVN OD value were subtracted from the averaged SON
and PVN OD values, respectively, in each image.

Semi-quantitative real-time RT-PCR
The rats were deeply anaesthetised with sodium pentobarbital (50 mg/kg,
i.p.) and perfused through the heart with ice-cold modified an artificial cerebral spinal fluid (aCSF) solution in which NaCl was replaced by equiosmolar
sucrose containing (in mM): 210 sucrose, 3 KCl, 2.0 CaCl2, 1.3 MgCl2,
1.24 NaH2PO4, 25 NaHCO3, 0.2 ascorbic acid and 10 D-glucose (pH 7.4). The
brains were removed and sliced in the coronal plane in ice-cold aCSF at a
thickness of 500 lm using a vibrating microtome (VT1200; Leica). SON tissues were collected from six age-matched male rats for each Wistar and
WKY strain using a punch-tool (inner diameter 1.0 mm) that allowed
obtaining tissue only from the SON.
The micropunched samples were placed in RNAlater (Qiagen, Valencia,
CA, USA) and stored at 20 °C until sampling from all the animals were
completed. Total RNA was isolated from the samples using TRI reagent
(Sigma-Aldrich, St Louis, MO, USA) after lysis in a tissue lyser (Qiagen). The
concentration and quality of the isolated RNA was determined using a
NanoDrop spectrophotometer (Thermo-Fisher Scientific, Waltham, MA, USA).
After DNaseI treatment, equal amount of RNA was reverse transcribed to
cDNA using oligo dT and M-MLV reverse transcriptase (Sigma-Aldrich). Realtime PCR was performed using SYBR Select Master Mix (ABI Applied Biosystems, Grand Island, NY, USA) with ABI ViiA-7 sequence detection system
(Applied Biosystems). Primers were specifically designed from exon spanning
region to exclude the potential amplification of any genomic DNA and to
amplify the cDNA of interest. The Primer sets used for MR were (forward:
50 -CTCCCTAACATGTCCTAGAAAAGC-30 and reverse: 50 -AGAACGCTCCAAGGTCT
GAG-30 ; accession # NM 013131.1) and cyclophilin B (forward: 50 -CTTGGTG
TTCTCCACCTTCC-30 and reverse: 50 -ACGTGGTTTTCGGCAAAGT-30 ; accession
#NM 022536.1). The RT-PCR reaction for each sample was performed in
triplicate and the average cycle threshold (Ct) was obtained. To normalise
the expression of MR, the differences in Ct (DCt) were obtained by subtracting the Ct of MR from Ct of cyclophilin B. The relative differences in the
expression of MR between Wistar and WKY rats were obtained by subtracting mean DCt and expressed as DDCt.

In situ hybridisation
Tissue preparation.

The brain sections were prepared as described
above with respect to immunocytochemistry.

Preparation of the probe. cDNA was prepared using total RNA
extracted from rat SON punches. From this cDNA, 11b-HSD2 PCR products
were made using a probe primer set (forward: GAT TTA GGT GAC ACT ATA
GAA ggacgtattgtgaccgttgg, reverse: CTAA TAC GAC TCA CTA TAG GGA C
gctggatgatgctgaccttg), which contains promoters for both Sp6 and T7 RNA
Journal of Neuroendocrinology, 2015, 27, 835–849
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polymerase. The amplified DNA was purified using a PCR clean up Column
(Sigma-Aldrich). A nonradioactive digoxigenin (DIG) RNA labelling kit (Roche
Diagnostics, Indianapolis, IN, USA) was used to synthesise sense and antisense DIG-labelled RNA probes for 11b-HSD2 using SP6 and T7 RNA polymerase (Roche Applied Science, Penzberg, Germany). This probe hybridises
with 760–910 nucleotides of 11b-HSD2. The transcription reaction was performed in accordance with the manufacturer’s protocol; briefly, 20 ll of the
reaction mixture containing 2 ll of the transcription buffer, 2 ll of the
labelling mixture, 2 ll of RNA polymerase and 1 lg of DNA were incubated
for 2 h at 37 °C. Free nucleotides were separated on the PCR clean up column (Sigma-Aldrich). A DIG-labelled RNA probe was added to the hybridisation buffer at 100 ng/ml and denatured at 75 °C for 10 min.

Hybridisation.

Free-floating brain sections were pre-incubated in
hybridisation buffer consisting of 200 mM NaCl, 10 mM Tris HCl (pH 7.5),
10 mM phosphate buffer, 5 mM ethylenediaminetetraacetic acid, 50% formamide, 10% dextran sulphate and 19 Dehardt’s solution at 55 °C for 1 h
on a rocker incubator (Boekel Scientific, Feasterville, PA, USA). The buffer
was then replaced with the denatured probe and incubated at the same
temperature overnight. Brain sections were then washed for 30 min with
the washing buffer (19 saline-sodium citrate buffer, 50% formamide, 0.1%
Tween 20). The washing process was repeated three times to ensure that
any residue components were removed. Subsequently, the sections were
treated with the blocking reagent (Roche) in 19 maleic acid buffer (MAB:
100 mM maleic acid and 150 mM NaCl, pH 7.5) for 1 h and were then incubated at room temperature for 2 h in alkaline phosphatase conjugated antiDIG antibody at 1 : 2000 dilution (Roche Applied Science). The brain sections were washed three times (10 min each) in 19 MAB-T (MAB containing
0.1% Tween 20). The hybrids were visualised in 5-bromo-4-chloro-3-indolyl
phosphate (BCIP)- nitroblue tetrazolium (NBT)- polyvinyl alcohol (PVA) solution [10% PVA in 100 mM Tris HCl (pH 9) containing 0.2 mM BCIP, 0.2 mM
NBT, and 5 mM MgCl2] at 30 °C. Colour development was terminated by
washing in water, and sections were mounted on gelatin coated microslides,
dehydrated in ethanol gradient, clarified in xylene and cover slipped with
permount. The brain sections were examined and images were acquired at
1280 9 1024 format with a light microscope (Nikon Eclipse 80i).

Control experiments.

To check for the specificity of the hybridisation
signals, sense versions of the probe were processed in parallel with the
experimental specimens and found to lack any labelling for 11b-HSD2. The
hybridisation was also tested on the kidney sections where the presence of
11b-HSD2 is known (44).

Double-labelling of 11b-HSD2 in situ hybridisation and MR
immunocytochemistry
The sections that were hybridised with the DIG-labelled11b-HSD2 probe
were incubated with sheep anti-digoxigenin antibody (0.5 lg/ml; Roche)
for 2 h at room temperature. The sections were then incubated for 2 h
with anti-sheep-antibody conjugated with DyLight 647 (dilution 1 : 400:
Jackson Immuno Research, West Grove, PA, USA). Subsequently, the hybridised sections were incubated with MR antibody as described above for
the immunocytochemistry and then labelled with anti-mouse antibody conjugated with DyLight 488 (dilution 1 : 400: Jackson Immuno Research). The
sections were washed three times for 10 min between each step with
appropriate buffers. Finally, sections were mounted in PVA with anti-fading
agent 1,4-diazabicyclo[2.2.2]octane (DABCO) that consists of 4.8 g PVA,
12 g glycerol, 12 ml dH2O, 24 ml 0.2 M Tris-HCl and 1.25 g DABCO. Brain
slices were examined and confocal images (TCS SP2 spectral confocal
microscope; Leica) were acquired at 1024 9 1024 format. The optical sections were 0.5 or 1 lm thick and viewed in stacks of 1–3 sections using
IMAGEJ (NIH).

© 2015 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of
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Single-cell RT-PCR
Single cell harvest for single-cell RT-PCR
Punched SON tissues were prepared as described above for the semi-quantitative real-time RT-PCR and were incubated in oxygenated aCSF (35 °C)
containing Protease Type XIV (1.2 mg/ml; Sigma Chemicals, St Louis, MO,
USA) for 20–30 min and washed in a solution consisting of (in mM): 140
sodium isethionate, 2 KCl, 4 MgCl2, 23 glucose and 15 HEPES (pH 7.3) (adjusted with 1 M NaOH). The enzyme-treated tissue was triturated in sodium
isethionate solution using three successively smaller fire-polished pipettes to
release individual MNC cell bodies. The supernatant containing dissociated
neurones was then transferred to a plastic Petri dish (Nunc, Rochester, NY,
USA) on an inverted microscope stage and allowed to settle for approximately 5 min. Glass capillary tubes for pipettes (Corning 7052 capillary
glass; Garner Glass, Claremont, CA, USA) were autoclaved to prevent RNase
contamination. Electrodes were pulled on a Flaming/Brown micropipette
puller (Model P-97; Sutter Instrument, Novato, CA, USA) and filled with
RNase free water. Positive pressure was applied when the electrode
approached a cell to minimise contamination (i.e. extracellular matrix, dead
cells, RNase). Dissociated MNCs can be easily and reliably identified by their
large cell size (> 16 lm in diameter). Negative pressure was applied to the
electrode to draw the cell into the electrode. Following aspiration, the contents of the electrode were ejected into an ice-cold 0.5 ml PCR tube and
stored at 80 °C.

First round multiplexed amplification
iTaq universal SYBR green one-step kit (Bio-Rad, Hercules, CA, USA) was
used to make cDNA and amplification of the transcript in the same tube
using gene specific primers. iTaq universal SYBR green mix, iScript reverse
transcriptase and mixture of gene specific primers (forward and reverse
primes for MR, 11b-HSD2, OT and VP) were added to the cell lysate, and
thermo-cycling parameters were set in accordance with the manufacturer’s
instructions: 10 min at 50 °C (reverse transcription) and 1 min at 95 °C
(polymerase activation and DNA denaturation) followed by 15 cycles of
amplification (10 s at 95 °C and 1 min at 60 °C).

PCR
The amplified templates generated in the first round were subjected to conventional PCR using a programmable thermal cycler (Bio-Rad) and primers
specifically designed to amplify the cDNA of interest (Table 1). The identification of each cDNA species is based on the predicted size of each PCR product
on agarose gel. Negative controls for contamination from extraneous and
genomic DNA from other sources were tested for each batch of neurones.

Results
Localisation of MR in the hypothalamus
Within the hypothalamic region, marked MR-immunoreactive neurones were observed only in the SON and PVN (Fig. 1A,B). Strong MR
immunoreactivity was largely confined to the cell body in a majority
of MNCs in the SON (Fig. 1C). Overall immunolabelling in the PVN was
weaker compared to that in the SON; however, prominent immunoreactive neurones were observed in the magnocellular region of the
PVN. Empirical evidence obtained in our laboratory showed that WKY
rats (Fig. 1A) consistently produce stronger MR immunoreactivity in
MNCs than do Wistar rats (Fig. 1B). Because this characteristic of

Table 1. Primer sequences used to detect gene expressions of interest.
Gene
11bHSD2
MR
OT
VP

F
R
F
R
F
R
F
R

Primer sequence

Amplicon size (bp)

50 -TCAGCCGTGTTCTGGAAATTA-30
50 -GGAAAGTTACCACTGGAGACAG-30
50 -GGTATCCCGTCCTAGAGTACAT-30
50 -AGATAGTTGTGTTGCCCTTCC-30
50 -GCCTGCTTGGCCTACTG-30
50 -CCGCAGGGAAGACACTTG-30
50 -CACCTATGCTCGCCATGAT-30
50 -GCTTCCGCAAGGCTTCT-30

123
196
109
299

WKY rats would allow us to obtain excellent MR immunocytochemical
images even in brain sections that were processed for in situ hybridisation, we compared the MR expression in the SON and PVN between
WKY rats and Wistar rats. Although the distribution of MR-immunoreactivity in WKY rats was similar, if not identical, to that of
Wistar rat, the intensity of the labelling in the SON and PVN measured as the optical density (OD) from WKY rats was significantly
greater than that from Wistar rats (Fig. 1E). In addition, semi-quantitative RT-PCR showed significantly greater expression of MR in the
SON of WKY rats than those of Wistar rats (Fig. 1F). Immunocytochemical localisation of MR was also performed on the sections from
the kidney (Fig. 1G) in which the localisation of MR is well established
(45–48). In the kidney cortex, an intense MR immunoreactivity was
present in the tubules where the cellular morphology and location
resembles that of the distal tubules. In the kidney medulla, a strong
11b-HSD2 immunoreactivity was present in collecting ducts.
Double-immunofluorescence confocal microscopy was also
employed to exam whether MR is expressed in both VP and OT synthesising MNCs in WKY rats (Fig. 2) as observed previously in
Sprague–Dawley rats (9). MR-immunoreactive MNCs were homogeneously located throughout the SON, although the intensity of the
immunoreactivity varied among the MNCs (Fig. 2A,D). By contrast,
the characteristic distribution of VP and OT neurones was observed.
VP immunoreactive neurones were more prevalent in the posterior–
ventral region of the nucleus (Fig. 2B), whereas OT immunoreactive
neurones were more predominantly located in the anterior–dorsal
region (Fig. 2E). Close observation revealed that all VP or OT
immunoreactive MNCs were also immunoreactive to MR as well
(Fig. 2C,F). In the PVN, MR-immunoreactive neurones of varying
intensities were populated in the posterior magnocellular subdivision (Fig. 2G,J). Immunocytochemical localisation of the VP and OT
also displayed the stereotypical distribution of VP and OT neurones
in the PVN. VP neurones were concentrated in the posterior magnocellular subdivision (Fig. 2H), whereas oxytocin neurones were
populated in the area surrounding the posterior magnocellular subdivision (Fig. 2K). As in the SON, all VP and OT immunoreactive
MNCs were also immunoreactive to MR in the PVN (Fig. 2I,L).

Localisation of 11b-HSD2 immunoreactivity in the
hypothalamus
The 11b-HSD2 antibody labelled essentially all neuronal nuclei in the
brain sections. Although this ubiquitous nuclear labelling was proba-

© 2015 The Authors. Journal of Neuroendocrinology published by John Wiley & Sons Ltd on behalf of
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Fig. 1. Immunocytochemical localisation of mineralocorticoid receptor (MR) in coronal section of the hypothalamus from Wistar–Kyoto (WKY) and Wistar rats.
(A, B) Prominent MR-immunoreactive neurones were observed only in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) within the hypothalamic
region in both WKY rats (A) and Wistar rats (B). (C, D) MR-immunoreactivity in the SON from a WKY rat (C) and a Wistar rat (D). (E) The intensity of the MR-labelling in the SON and PVN was measured as the optical density (OD) and normalised to OD values of nonspecific staining areas outside the SON or PVN. The
mean normalised OD value of the SON from WKY rats was significantly higher than that from Wistar rats (n = 6 for both strains; *P = 0.0021). (F) Relative
expression of MR-mRNA in the SON and PVN was significantly higher in WKY rats than in Wistar rats (n = 6 for both strains; *P = 0.0271). (G) Immunocytochemical localisation of MR was also performed in the kidney. An intense MR immunoreactivity was present in the tubules where the cellular morphology and
location resembles that of the distal tubules of the kidney cortex (arrows). In the kidney medulla, a strong 11b-hydroxysteroid dehydrogenase type 2
immunoreactivity was present in collecting ducts (arrowheads). OC, optic chiasm. Scale bar = 250 lm in (B), 50 lm in (D) and 1 mm in (G).

bly a result of nonspecific labelling, at a lower power view, the
immunoreactivity was most dense in the PVN and SON (Fig. 3A). At
higher power views, 11b-HSD2 immunoreactivity was specifically
observed in the cytoplasm of the MNCs in the SON (Fig. 3B). In the
PVN, cytoplasmic immunoreactivities appeared to be confined to the
soma of MNCs in the posterior magnocellular cluster (Fig. 3C). Brain
sections obtained from the rats used for MR immunocytochemistry
were also treated with the 11b-HSD2 antibody. No noticeable differences were evident in the staining intensities between the rat strains
(data not shown). The 11b-HSD2 antibody was also tested on the
sections from the kidney (Fig. 3E), which is known to express 11bHSD2 (44,49). In the kidney cortex, an intense 11b-HSD2 immunoreactivity was present in the tubules, for which the cellular morphology
and location resemble that of the distal tubules. In the kidney
medulla, a strong 11b-HSD2 immunoreactivity was present in collecting ducts. The expression pattern of the 11b-HSD2 in the kidney
was comparable to that characterised in previous studies (44,49).

weak ubiquitous labelling of cell nuclei was observed elsewhere in the
brain section, prominent hybridisation labelling in the cytoplasm was
seen only in the PVN and SON (Fig. 4A). Within the PVN, labelling
showed the well characterised ‘butterfly wing’ shape with more
prominent labelling in the posterior magnocellular region; however,
noticeable labelling was also observed in the parvocellular regions as
well (Fig. 4B). Somewhat more discrete cytoplasmic labelling was
found in the SON (Fig. 4C). The sense probe that was processed in
parallel with the experimental brain sections did not produce any
detectable labelling (Fig. 4D). In addition, in situ hybridisation of 11bHSD2 was performed on the kidney sections. The expression pattern
of the in situ labelling in the kidney resembled that of the immunoreactivity (i.e. the intense hybridisation labelling was present in the
tubules where the cellular morphology and location resembles that of
the distal tubules of the kidney cortex). Also, strong hybridisation
labelling was present in collecting ducts in the kidney medulla.

In situ hybridisation of 11b-HSD2 in the hypothalamus

Co-localisation of MR and 11b-HSD2 in MNCs of the SON
and PVN

In situ hybridisation with a labelled antisense RNA probe was used to
localise a specific 11b-HSD2 mRNA in the hypothalamus. Although

11b-HSD2 in situ hybridised sections were subsequently processed
for MR immunocytochemistry using a double-fluorescent labelling
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Fig. 2. Colocalisation of mineralocorticoid receptor (MR) immunoreactivity with both vasopressin (VP)-neurophysin (NP) and oxytocin (OT)-NP immunoreactivity in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) from a Wistar–Kyoto (WKY) rat. All confocal photomicrographs are in a coronal 3-lm
optical section. MR-immunoreactivity was labelled with DyLight 488-conjugated secondary antibody (pseudo-coloured in green). VP-NP and OT-NP immunoreactivities were labelled with DyLight 649-conjugated secondary antibody (pseudo-coloured in red). (A, D) MR-immunoreactivity in the SON. Most magnocellular
neurosecretory cells (MNCs) in the SON appeared to possess some degree of MR-immunoreactivity in their cell bodies. (B) VP-NP immunoreactivity in the same
section and optical plane as in (A). (C) A merged image of (A) and (B) demonstrated that all the VP-NP immunoreactive MNCs retain MR-immunoreactivity. (E)
OT-NP immunoreactivity in the same section and image plane as in (D). (F) A merged image of (D) and (E) demonstrated that all OT-NP immunoreactive MNCs
possess MR immunoreactivity. (G, J) MR-immunoreactivity in the PVN. Although the MR-immunoreactivity was not robust as in the SON, a prominent MR
immunoreacitivty was observed in MNC within the PVN. Most of these MR-immunoreactive MNCs are located in a cluster of cells in the posterior magnocellular region. (H) VP-NP immunoreactivity in same section and image plane as in (G). Note that the VP-NP immunoreactive cells form a cluster in the lateral portion of the PVN. (I) A merged image of (G) and (H) showed that all VP-NP immunoreactive MNCs expressed MR-immunoreactivity. (K) OT-NP immunoreactivity
in same section and image plane as in (J). (L) Merged images of (J) and (K) revealed that MR-immunoreactivity is colocalised with OT-NP immunoreactivity
within MNCs in the PVN. Scale bar = 50 lm in (A) and 100 lm in (G).

technique with confocal microscopy. Several WKY rats were used
for this because robust MR-immunoreactivity remained following
in situ hybridisation in the PVN (Fig. 5A) and SON (Fig. 5D). All

MR-immunoreactive MNCs had 11b-HSD2 hybridisation labelling in
the PVN (Fig. 5B,C) and SON (Fig. 5E,F). Confocal images at 1 lm
optical sections acquired with a 9 100 objective lens allowed us to
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Fig. 3. Immunocytochemical localisation of 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) in sections of the hypothalamus and kidney from a Wistar–Kyoto (WKY) rat. (A) 11b-HSD2 immunoreactivity was observed in essentially all neuronal nuclei in the brain section. This ubiquitous nuclear labelling was
most likely nonspecific labelling; however, the immunoreactivity was dense in the paraventricular nucleus (PVN) and supraoptic nucleus (SON). (B) In the SON,
magnocellular neurosecretory cells (MNCs) containing cytoplasmic immunoreactivity were observed. Note that cells outside of the SON are devoid of cytoplasmic immunoreactivity. (C) In the PVN, the cells possessing cytoplasmic immunoreactivity were mostly located in the posterior magnocellular cluster. (D) A higher
power view demonstrates cytoplasmic immunoreactivity in MNCs in the PVN. (E) Immunocytochemical localisation of 11b-HSD2 was also performed in the kidney. In the kidney cortex, an intense 11b-HSD2 immunoreactivity was present in the tubules for which the cellular morphology and location resemble that of
the distal tubules (arrows). In the kidney medulla, a strong 11b-HSD2 immunoreactivity was present in collecting ducts (arrowheads). OC, optic chiasm. Scale
bar = 500 lm in (A) and (E), 50 lm in (B–D).

observe the subcellular distribution of 11b-HSD2 hybridisation
labelling and MR immunoreactivity. Immunoreactivity to MR was
observed demonstrating a distinct granular appearance clumped in
the perinuclear zone of the cytoplasm, although immunoreactivity
was also observed diffusely within the entire cytoplasm (Fig. 5G). By
contrast, 11b-HSD2 hybridisation labelling was stronger in the
peripheral region of the cytoplasm (Fig. 5H). A merged image
demonstrated a subcellular distribution difference of MR
immunoreactivity and 11b-HSD2 hybridisation labelling (Fig. 5I).

absolute levels of OT- and VP-mRNAs are unknown and therefore
the phenotypes of the MNCs were not defined. cDNA from each
MNC was amplified by PCR for MR and 11b-HSD2. Out of seventyfive MNCs, amplified products of expected sizes for MR and 11bHSD2 were obtained from fifty-six (74.7%) and twenty-four (32.0%)
MNCs, respectively. Of fifty-six MNCs expressing MR, twenty-one
(37.5%) MNCs also expressed 11b-HSD2. The incidence of MR and
11b-HSD2 co-expression did not differ significantly among individual rats or between strains. Representative single-cell RT-PCR gel
images from a WKY rat are shown in Fig. 6.

Single-cell RT-PCR detection of MR and 11b-HSD2 mRNA
Seventy-five dissociated cells were collected individually from three
Wistar rats and three WKY rats. Typically, 12–15 cells were harvested from each animal. Following total RNA extraction and
reverse-transcription from these single cells, PCR for VP and OT
were performed. Either or both VP- and OT-mRNA were detected
from all dissociated neurones, confirming that the collected cells
were MNCs. Co-localisation of OT- and VP-mRNA was found in
most MNCs. Several other studies also demonstrated the co-localisation of both mRNAs in MNCs even though they are phenotypically different (50–52). Because our assay was not quantitative, the
Journal of Neuroendocrinology, 2015, 27, 835–849

Discussion
Expression of MR in the SON and PVN of the WKY rat
The present study demonstrated that the expression of MR in the
SON and PVN is greater in WKY rats than in Wistar rats. We determined that MR is expressed in both VP and OT MNCs in WKY rats
in accordance with our previous finding in Sprague–Dawley rats
(9,16–19). Because in situ hybridisation caused an increase in background staining in immunocytochemistry at the same time as
diminishing specific MR-immunolabelling, double-labelling of 11b-
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Fig. 4. In situ hybridisation detection of 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) mRNA in the hypothalamus of a Wistar–Kyoto (WKY) rat. (A)
Weak ubiquitous labelling of cell nuclei was observed elsewhere in the brain section; however stronger hybridisation labelling was seen in the paraventricular
nucleus (PVN) and supraoptic nucleus (SON) in which cytoplasmic labelling were present in neurones. (B) Within the PVN, more prominent cytoplasmic labelling
was observed in the posterior magnocellular region; however, noticeable cytoplasmic labelling was also observed in the parvocellular regions as well. (C) Discrete cytoplasmic labelling was found in magnocellular neurosecretory cells (MNCs) in the SON. (D) The sense probe that was processed in parallel with the
experimental bran sections did not produce detectable labelling in the SON. (E) In situ hybridisation of 11b-HSD2 was also performed in the kidney. The expression pattern of the in situ labelling in the kidney was resembled to that of immunoreactivity (Fig. 3E). An intense hybridisation labelling was present in the distal tubules in the cortex (arrows) and in the collecting ducts in the medulla region (arrowheads). OC, optic chiasm. Scale bar = 500 lm in (A), 100 lm in (B),
50 lm in (C) and (D), and 1 mm in (E).

HSD2 in situ hybridisation and MR immunocytochemistry was particularly challenging. As a result of the higher expression of
hypothalamic MR in WKY rats, obtaining decent images of MR
immunolabelling in 11b-HSD2 in situ hybridised brain sections
became possible. Thus, the WKY strain is an amenable strain for
investigating the co-localisation of MR and11b-HSD2 in MNCs.
The WKY rat is a normotensive back strain of the spontaneously
hypertensive rat (SHR), which is a well-studied animal model of
human essential hypertension (53). Thus, WKY rats have been used
as appropriate control for SHR. A recent report showed that the
SHR strain has an elevated hypothalamic MR mRNA, as well as an
increased number of MR-immunopositive cells in the magnocellular
paraventricular region, compared to that from WKY rats (20). The
increased expression of MR in the PVN of SHR rats most likely contributes to the development of hypertension because i.c.v. infusion
of the MR-antagonist caused a significant decrease in blood pressure (20). An intriguing point is that the normotensive WKY rats
have already considerably greater MR expression in the SON and
PVN compared to another normotensive Wistar rats. Thus, SHR that
reportedly have even greater hypothalamic MR expression was
developed for higher blood pressure by selective breeding of
the WKY stock (53), which already has elevated hypothalamic
MR-expression.

11b-hydroxysteroid dehydrogenase activity in the
hypothalamus
The present study investigates whether the glucocorticoid-inactivating enzyme, 11b-HSD2, is located in MR expressing MNCs in the
hypothalamic SON and PVN. Double-immunocytochemistry showed
that all MR immunoreactive neurones were also immunoreactive to
VP or OT. Double-labelling using immunocytochemistry and in situ
hybridisation demonstrated that all MR immunoreactive MNCs were
also labelled with11b-HSD2 in situ hybridisation. Although MR and
11b-HSD mRNAs were not detected in all harvested MNCs in single-cell RT-PCR, MR and 11b-HSD2 mRNAs were detected in 74.7%
and 32% of harvested MNCs, respectively. Moreover, 11b-HSD2
mRNA was detected in 37.5% of MR expressing MNCs identified by
single-cell RT-PCR. Failure to detect MR and 11b-HSD2 mRNA in
all cells with single-cell RT-PCR was probably a result of the minute
amount of the mRNAs that may be ruined during the process in
some cells rather than the absence of the mRNAs. Based on our
past single-cell RT-PCR assays (9,54), it is rare to detect certain
mRNA from every single MNC unless the mRNA is expressed abundantly such as VP and OT mRNAs. Nonetheless, our findings
strongly suggest that MR-expressing VP and OT MNCs also express
11b-HSD2. The co-localisation of MR and 11b-HSD2 in MNCs
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Fig. 5. Double fluorescent labelling of 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) in situ hybridisation and mineralocorticoid receptor (MR)
immunocytochemistry. MR immunoreactivity was labelled with DyLight 488-conjugated secondary antibody (pseudo-coloured in green). (A, D) Intense
immunoreactivity to MR was observed in the MNCs in the paraventricular nucleus (PVN) (A) and supraoptic nucleus (SON) (D). (B, E) 11b-HSD2 hybridisation
materials were labelled with DyLight 649-conjugated secondary antibody (pseudo-coloured in blue) in same section and image plane as in (A) and (D). The
11b-HSD2 hybridisation materials were observed in the magnocellular neurosecretory cells (MNCs) in the PVN (B) and SON (E). (C, F) The merged images
revealed that all MR immunoreactivity was co-localised with vasopressin (VP) 11b-HSD2 hybridisation materials within the MNCs in the PVN (C) and SON (F).
(G, H) Confocal images at 1 lm optical section acquired with a 9 100 objective lens were obtained to observe the subcellular distribution of MR immunoreactivity (G) and 11b-HSD2 hybridisation labelling (H) in the SON MNCs. Intense MR immunoreactivity was clumped in the perinuclear zone of the cytoplasm with
a distinct granular appearance along with more diffuse immunoreactivity within the entire cytoplasm (G). Strong 11b-HSD2 hybridisation labelling was
observed in the peripheral region of the cytoplasm (H). (I) A merged image demonstrated that MR immunoreactivity was co-localised with 11b-HSD2 hybridisation product in MNCs, although their subcellular distributions were different from each other. Scale bars = 50 lm.
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Fig. 6. Single cell reverse transcriptase-polymerase chain reaction detection
of transcripts in individual dissociated magnocellular neurosecretory cells
(MNCs) from a Wistar–Kyoto (WKY) rat. Libraries of cDNA were derived from
twelve cells dissociated from punched supraoptic nucleus (SON) tissue from
a WKY rat. All cells had mRNA for vasopressin (VP) and oxytocin (OT), confirming they were MNCs. Of these MNCs, mineralocorticoid receptor (MR)
mRNA was found in MNCs except #3 and 7; 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2) mRNA was found in cells #1, 4, 7, 8 and 10. Thus,
mRNAs for MR and 11b-HSD2 were colocalised in four MNCs (#1, 4, 8 and
10) out of 12 MNCs isolated. Both MR and 11b-HSD2 mRNAs were found
in cDNA library derived from punched SON tissues. M, Marker; N, Negative
control.

suggests further that MNCs in the SON and PVN are aldosteronesensitive neurones.
The presence of an hydroxyl group at position C-11 of the steroid structure of glucocorticoids is important for its biological activity because conversion of this group into a keto group inactivates
the steroid (55). The principal glucocorticoids, cortisol in human
and corticosterone in rodents, possess a hydroxyl group at C-11
and are active steroids. Conversion of the C-11 hydroxyl group into
a keto group of cortisol and corticosterone results in the conversion
of these active steroids into inactive cortisone and 11-dehydrocorticosteone, respectively. Two microsomal isozymes of 11b-hydroxysteroid dehydrogenase, 11b-HSD1 and 11b-HSD2, are known to
catalyze this conversion, and tissue-specific expression of these isozymes promote pre-receptor regulation of glucocorticoid and mineralocorticoid receptor activation (56).
Activity of 11b-HSD is documented in the hypothalamus. A
prominent formation of 11-dehydrocorticosterone from corticosterone was observed in incubated hypothalamic minces from rats
(57). Moreover, microinjection of the 11b-HSD inhibitors, carbenoxolone or glycyrrhizic acid, directly into the PVN caused an increase
in mean arterial pressure, heart rate and renal sympathetic nerve
activity (35). The inhibition of 11b-HSD likely permitted corticosterone to activate MRs because i.c.v. infusion of the MR antagonist,
spironolactone, blocked the effect of the 11b-HSD inhibitors (35).
However, these findings did not confirm whether the dehydrogenase activity was a result of 11b-HSD1 or to 11b-HSD2.
By contrast to 11b-HSD2, which has a limited expression, 11bHSD1 is abundantly expressed throughout the brain (58–61) including the PVN (41). Unlike 11b-HSD2, which exclusively catalyses the
hydroxysteroid dehydrogenase activity that converts biologically
active glucocorticoids into biologically inactive metabolites, 11bHSD1 is a bidirectional enzyme that also mediates the reverse
reaction; keto-glucorticoid reductase activity converts inactive

metabolites into potent glucocorticoids (62–65). The direction of
the enzymatic activities depends upon the availability of the cofactors, the oxidised/reduced forms of nicotinamide adenine dinucleotide phosphate (NADP+/NADPH). The reductase activity of 11bHSD1 requires NADPH as a cofactor, whereas its dehydrogenase
activity requires NADP+ (29). The production of NADPH requires
another microsomal enzyme, hexose-6-phosphate dehydrogenase
(H6PDH), which catalyzes glucose-6-phosphate oxidation to generate NADPH from NADP+ for 11b-HSD1 in the endoplasmic reticulum lumen (66). Thus, in the absence of H6PDH, 11b-HSD1 uses
NADP+ and primarily acts as a dehydrogenase (66–69). Recently,
colocalisation of MR and 11b-HSD1 immunoreactivities was
reported in some identified preautonomic neurones in the PVN.
Because no immunoreactivity to H6PDH was found in these MR11b-HSD1 immunoreactive neurones, it is proposed that 11b-HSD1
in the preautonomic neurones acts mainly act as a dehydrogenase
and facilitates the binding of aldosterone to MR (41). The same
study also demonstrated the presence of 11b-HSD1 immunoreactivity in MNCs of the PVN. Although the study did not specifically
address the colocalisation of 11b-HSD1 and MR in MNCs, the
absence of H6PDH immunoreactivity in the PVN implies that 11bHSD1 may act as a dehydrogenase in MNCs in the PVN.
Previous studies demonstrated that 11b-HSD2 is located to the
membrane of the endoplasmic reticulum (ER) with its active site
and co-factor binding domain facing the cytosol (70) where aldosterone is presumably located, and binds to its substrate with an
affinity approximately 100 times that of 11b-HSD1 (71–73). By
contrast, the intracellular localisation of 11b-HSD1 is located within
the lumen of the ER where H6PDH may generate NADPH (70),
which may explain why 11b-HSD1 acts as a reductase in most cells
unless the cells are disrupted (56). Consequently, if the two
enzymes are co-expressed, the higher binding affinity of 11b-HSD2
to the substrate and the specific intracellular localisation of 11bHSD2 result in 11b-HSD2 playing a more dominant role in corticosteroid metabolism in tissues (56). Thus, these findings suggest that
a limited amount of 11b-HSD2 suffices to protect MR from glucocorticoids in the MNCs.

Possible roles of MR-mediated aldosterone in MNCs
The effect on blood pressure of MR-mediated aldosterone in the
brain is well-established by a number of studies (74–76). Many of
these studies involved i.c.v. infusion of aldosterone and/or specific
MR blockers, and demonstrated that aldosterone activation of MR
in the brain increases release of VP and blood pressure via enhancing the sympathetic drive to the kidney, heart and vascular smooth
muscle (77–79). Intriguingly, i.c.v. infusion of ENaC blockers, amiloride or benzamil, prevented both the hypertension induced by i.c.v.
infusion of aldosterone in SD rats (80) and the salt-induced hypertension in Dahl-salt-sensitive (SS) rats (81,82). Although these studies provide only limited information regarding brain site(s) or cell
type(s) responsible for the MR-mediated aldosterone action, their
findings indicate that brain structures expressing MR, 11b-HSD2
and ENaC not only have the ability to modulate sympathetic drive
and VP release, but also are the sites for aldosterone action.
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Expression of MR in the brain was previously documented in the
choroid plexus, ependyma, neurones in the SON and PVN, the
nucleus tractus solitarius and in the subfornical organ
(9,16,18,40,83). Of these MR-expressing structures, both mRNA and
proteins for all three ENaC subunits (a, b, and c) were found in
MNCs of the SON and PVN, choroid plexus, and ependyma
(9,16,18,40,83). Of the brain structures that express MR and ENaC,
the SON and PVN are the only brain structures that directly
affect both neuroendocrine (VP release) and autonomic responses
in the regulation of blood pressure. However, the mechanism of
how aldosterone-MR influences the activity of the MNCs is
unknown.
Previously, we demonstrated that ENaCs in MNCs mediate a Na+
leak current and modulate the membrane potential (84) that affect
the frequency and pattern of action potentials. Because the release
of neurohypophysial hormones largely depends upon the neuronal
activity of MNCs (2,10) and because somato-dendritic release of VP
within the PVN affects presympathetic neurones (8), we proposed a
novel theoretical concept where ENaCs modulate the frequency of
action potentials in MNCs that modulate neuroendocrine and autonomic responses, which, in turn, contribute to cardiovascular homeostasis.
In aldosterone-sensitive epithelia of the kidney, the activation of
MR by aldosterone not only regulates gene expression of ENaC subunits (11–15), but also a variety of genes, including those for regulatory proteins for ENaCs. The serum- and glucocorticoid-inducible
kinase 1 (SGK1) is one of the ENaC regulatory proteins that is also
promoted by aldosterone-MR activation (85,86). The effects of
SGK1 on ENaC activity were extensively studied in aldosterone-sensitive epithelia. Activated SGK1 directly increased a-ENaC transcription (87,88), disrupted ENaC internalisation from the cell membrane
(89–91) and increased channel open probability (92). Because SGK1
is expressed in the SON and PVN of the rat brain (34), multiple
levels of regulation, synthesis and translocation of ENaC by MR
likely occur in MNCs.
Dietary salt intake is known to affect the production and
release of the sodium-retaining hormone, aldosterone, from the
adrenal cortex (93–95). Plasma aldosterone concentrations are low
in rats maintained on a normal or high-salt diet. By contrast, the
plasma concentration of aldosterone increased in rats maintained
on a low-salt diet. Aldosterone concentration in the hypothalamus is also affected by dietary salt intake. However, the concentration of aldosterone in the hypothalamus in Dahl-SS rats
reportedly increased, not decreased, with high dietary salt intake
(82,96,97). In addition, i.c.v. infusion of Na+-rich artificial CSF
caused an increase in hypothalamic aldosterone concentration
and blood pressure (98). Importantly, the increase in both
hypothalamic aldosterone and blood pressure was prevented by
i.c.v. infusion of an aldosterone synthase inhibitor (98). These
results suggest that, in response to elevated Na+ concentration in
the CSF or increased dietary salt intake, aldosterone is synthesised
in the hypothalamus independent of the adrenal cortex. Transcripts of aldosterone synthase, CYP11B2, were detected in various brain regions including the hypothalamus (99). Moreover, SS
hypertension in Dahl-SS rats is alleviated by central infusion of
Journal of Neuroendocrinology, 2015, 27, 835–849
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several inhibitors of steroid synthesis, including one specific for
aldosterone synthase (68,96). Local aldosterone synthesis suggests
that there may be sufficient aldosterone concentrations in the
immediate vicinity of MR-expressing MNCs that would result in
elevated binding of aldosterone on MRs in the MNCs. Thus, a
large amount of 11b-HSD2 may not be necessary in the MNCs
of the SON and PVN.
Dietary salt intake is also known to be affected by aldosterone.
Several studies showed that aldosterone induces salt appetite
when its release is increased in response to sodium deficiency
(100–103). Aldosterone induces sodium appetite through MR in
the brain because infusion of aldosterone into the fourth ventricle alone resulted in increased sodium appetite, which was
blocked by an MR antagonist (104). One of the potential brain
areas mediating the aldosterone induced sodium appetite is the
MR and 11b-HSD2 co-expressing neurones in the nucleus tractus
solitarius (40). By contrast, several studies have demonstrated
that centrally released OT mediates the inhibition of sodium
appetite (105–109), whereas OT release into the general circulation does not appear to be involved in the inhibition of sodium
appetite (110). Interestingly, treatment with a precursor of aldosterone, deoxycorticosterone acetate, caused a decrease in neuronal
activity of OT neurones in the SON and PVN (111–113). Thus, the
presence of MR and 11b-HSD2 in OT neurones implies that
aldosterone directly inhibits these neurones via the MR. The inhibitory effect of aldosterone on OT neurone may be necessary
during hypernatraemia, the condition known to decrease sodium
appetite (105,114–116). Because the sodium concentration in the
cerbrospinal fluid (CSF) is elevated during hypernatraemia (117)
and a high concentration of sodium in CSF causes an increase in
hypothalamic aldosterone concentration (98), inhibition of sodium
appetite caused by the elevated CSF sodium concentration
(114,118,119) may be mediated by the central aldosterone via MR
in OT neurones.

Conclusions
The present study demonstrates that the glucocorticoid-inactivating enzyme, 11b-HSD2, is located in MR expressing OT and VP
MNCs in the SON and PVN. These findings strongly suggest that
MR in MNCs are mostly regulated by aldosterone. Considering
the roles of VP and OT in the fluid/electrolyte balance, the colocalisation of MR and 11b-HSD2 suggests that the effect of central aldosterone on blood pressure is mediated, at least partly, via
MR in MNCs.
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